Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Clarivate Q3 Adjusted Earnings Rise, Revenue Falls; Q4 Guidance Set

Clarivate Q3 Adjusted Earnings Rise, Revenue Falls; Q4 Guidance Set

MT newswireMT newswire2026/11/03 10:54
06:54 AM EST, 11/03/2026 (MT Newswires) -- Clarivate (CLVT) reported Q3 adjusted earnings Tuesday of $0.21 per diluted share, up from $0.18 a year earlier. Analysts surveyed by FactSet expected $0.18. Revenue for the quarter ended Sept. 30 was $567.9 million, down from $623.1 million a year earlier. Analysts expected $566.8 million. For Q4, the company expects adjusted EPS of $0.14 to $0.18. Analysts expect $0.18. Clarivate also expects Q4 revenue of $490 million to $510 million. Analysts expect $562.8 million. For 2026, the company said it updated its outlook, now expecting adjusted EPS of $0.73 to $0.77 and revenue of $1.97 billion to $1.99 billion. Analysts expect $0.74 and $2.30 billion, respectively. Shares of the company were down 6.6% in Tuesday premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss